Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines

Zulma Gazit*, David W. Weiss, Daniel Shouval, Michal Yechezkeli, Volker Schirrmacher, Michael Notter, Jürgen Walter, Eli Kedar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The antitumor effects of chemotherapy, recombinant human interleukin-2 (IL-2), recombinant human interferon α A/D (IFNα), allogeneic human lymphokine-activated killer (LAK) cells, and antitumor monoclonal antibody (mAb), administered alone and in various combinations, were tested in athymic nude mice carrying human tumor xenografts. Treatment began 6-18 days after i.v. or i.p. inoculation of colorectal carcinoma or melanoma cell lines, when macroscopic growths were evident. Chemotherapy consisted of two or three courses of 5-fluorouracil (5-FU) or dacarbazine. IL-2 and/or IFNα were administered three to five times weekly for 1-3 weeks, usually starting 2-5 days after chemotherapy. Human LAK cells were infused once or twice weekly for 2 or 3 weeks concurrently with IL-2. In some experiments, murine anticolorectal carcinoma mAb (SF25) was administered. In both tumor systems, chemotherapy alone or immunotherapy alone (IL-2, IL-2 + LAK cells, IFNα, IL-2 + IFNα ± LAK cells) had little or no therapeutic effects. Additive effects were obtained by combining chemotherapy with IL-2 and LAK cells or with IL-2 and IFNα. In the majority of the experiments, the most effective combination was chemotherapy + IL-2 + IFNα + LAK cells. Treatment with mAb was beneficial in the colorectal carcinoma system when combined with 5-FU + IL-2 or 5-FU + IL-2 + IFNα. Homing experiments with radiolabeled human and mouse LAK cells injected i.v. showed increased early accumulation in the liver and lungs, whereas freshly explanted mouse splenocytes localized mostly in the spleen and liver. The tissue distribution pattern of human LAK cells was similar in normal and tumor-bearing mice (with lung metastases). These findings suggest that combination of chemotherapy with cytokines and LAK cells can be partially effective for advanced solid human tumors even in the absence of the host's T-cell immune response. Preliminary experiments showed that tumor-specific, anti-melanoma T-cell clones were effective in local (s.c.) tumor growth inhibition (Winn assay) following coinjection with the autologous tumor cells.

Original languageEnglish
Pages (from-to)135-144
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume35
Issue number2
DOIs
StatePublished - Mar 1992

Keywords

  • Chemo-adoptive immunotherapy
  • Cytokines
  • Human tumor xenografts
  • T cells

Fingerprint

Dive into the research topics of 'Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines'. Together they form a unique fingerprint.

Cite this